Pulmonary Condensate: Non-invasive Evaluation of Pulmonary Involvement in Asthma and Cystic Fibrosis.

Launched by THE INSTITUTE OF MOLECULAR AND TRANSLATIONAL MEDICINE, CZECH REPUBLIC · Nov 5, 2019

Keywords

ClinConnect Summary

This clinical trial is exploring a new way to understand lung health in patients with asthma and cystic fibrosis (CF) by analyzing something called exhaled breath condensate (EBC). EBC is simply the water vapor we breathe out, which can contain important markers that reveal information about lung inflammation and infections. Researchers believe that by studying the "breathprints" found in EBC, they can identify specific signs of lung issues, helping to diagnose and monitor the severity of conditions like asthma and CF, particularly infections caused by certain bacteria.

To participate in this trial, individuals must be children or adults with moderate or allergy-related asthma, or those diagnosed with cystic fibrosis. Healthy individuals without any lung disorders can also join as a comparison group. Throughout the study, participants will provide breath samples, which will be analyzed to identify these important biomarkers. This research could lead to better ways to monitor and treat lung diseases, making it an essential step in improving care for asthma and CF patients. If you or a loved one meet the eligibility criteria, this trial could offer a chance to contribute to important medical advancements.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Children/adults with moderate or IgE mediated asthma
• • Children/adults with cystic fibrosis
• • Healthy control children/adults without lung disorders
• Exclusion Criteria:
• • -